X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ceritinib (329) 329
crizotinib (226) 226
oncology (175) 175
index medicus (170) 170
chemotherapy (150) 150
humans (139) 139
alectinib (125) 125
anaplastic lymphoma kinase (107) 107
open-label (107) 107
lung neoplasms - drug therapy (88) 88
carcinoma, non-small-cell lung - drug therapy (87) 87
cell lung-cancer (86) 86
alk (78) 78
mutation (78) 78
resistance (76) 76
lung cancer (72) 72
lymphomas (68) 68
nsclc (62) 62
protein kinase inhibitors - therapeutic use (59) 59
lung cancer, non-small cell (57) 57
non-small cell lung cancer (57) 57
lung neoplasms - genetics (56) 56
receptor protein-tyrosine kinases - genetics (52) 52
carcinoma, non-small-cell lung - genetics (51) 51
male (51) 51
antineoplastic agents - therapeutic use (50) 50
receptor protein-tyrosine kinases - antagonists & inhibitors (48) 48
female (47) 47
hemic and lymphatic diseases (47) 47
cancer (46) 46
respiratory system (45) 45
brain metastases (44) 44
middle aged (44) 44
pyrimidines - therapeutic use (44) 44
protein kinase inhibitors - pharmacology (42) 42
lung neoplasms - pathology (41) 41
metastasis (41) 41
safety (41) 41
crizotinib resistance (40) 40
kinases (39) 39
pharmacology & pharmacy (39) 39
sulfones - therapeutic use (38) 38
acquired-resistance (36) 36
adult (36) 36
animals (36) 36
brigatinib (36) 36
cancer therapies (36) 36
carcinoma, non-small-cell lung - pathology (34) 34
single-arm (34) 34
pyrazoles - therapeutic use (31) 31
pyridines - therapeutic use (31) 31
eml4-alk fusion gene (30) 30
mutations (29) 29
treatment outcome (29) 29
antineoplastic agents - pharmacology (28) 28
care and treatment (28) 28
inhibitors (28) 28
non-small cell lung carcinoma (28) 28
patients (28) 28
aged (27) 27
alk inhibitors (27) 27
lymphoma (27) 27
identification (26) 26
inhibitor (26) 26
tumors (26) 26
eml4-alk (25) 25
non-small-cell lung cancer (25) 25
receptor protein-tyrosine kinases - metabolism (25) 25
survival (25) 25
cell line, tumor (24) 24
hematology, oncology and palliative medicine (24) 24
protein-tyrosine kinase (24) 24
pyrimidines - pharmacology (24) 24
drug resistance, neoplasm (23) 23
article (22) 22
drug therapy (22) 22
sulfones - pharmacology (21) 21
egfr (20) 20
genetic aspects (20) 20
lorlatinib (20) 20
metastases (20) 20
review (20) 20
tyrosine (20) 20
drug resistance, neoplasm - genetics (19) 19
proteins (19) 19
alk inhibitor (18) 18
antitumor-activity (18) 18
drug resistance (18) 18
gefitinib (18) 18
gene (18) 18
gene rearrangement (18) 18
neoplasms. tumors. oncology. including cancer and carcinogens (18) 18
pulmonary/respiratory (18) 18
research (18) 18
tyrosine kinase inhibitors (18) 18
analysis (17) 17
brain neoplasms - secondary (17) 17
clinical trials (17) 17
editorial (17) 17
multicenter phase-ii (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Internal Medicine, ISSN 0918-2918, 2019
We herein report a 75-year-old woman with insulin-treated diabetes and metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who... 
hyperglycemia | insulin resistance | ceritinib
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2251 - 2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)... 
TRIALS | ONCOLOGY | CERITINIB | ADENOCARCINOMA | ALECTINIB | INHIBITORS | PHASE-3 | RETROSPECTIVE ANALYSIS
Journal Article
by Qi, XL and Ma, W and Li, S and Zhou, CC
LUNG CANCER, ISSN 0169-5002, 08/2014, Volume 85, Issue 2, pp. 335 - 336
Journal Article
NATURE CHEMICAL BIOLOGY, ISSN 1552-4450, 12/2017, Volume 13, Issue 12, pp. 1204 - 1204
The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule... 
CERITINIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMOTHERAPY
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 16, pp. 1370 - 1379
PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical... 
ONCOLOGY | CERITINIB | ALECTINIB | CRIZOTINIB | OPEN-LABEL | INHIBITOR | ROS1 | PF-06463922
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5686 - 5696
Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a standard therapy for patients with ALK-rearranged non-small cell lung cancer... 
CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | NVP-TAE684 | ONCOLOGY | CERITINIB | EML4-ALK FUSION GENE | SENSITIVITY | CH5424802 | CRIZOTINIB RESISTANCE | NEUROBLASTOMA | IDENTIFICATION | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Lung Neoplasms - metabolism | Tomography, X-Ray Computed | Dose-Response Relationship, Drug | Piperidines - pharmacology | DNA Mutational Analysis | Inhibitory Concentration 50 | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Pyridines - therapeutic use | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Models, Molecular | Lactams, Macrocyclic - pharmacology | Benzoquinones - pharmacology | Drug Resistance, Neoplasm - genetics | Receptor Protein-Tyrosine Kinases - genetics | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Lung Neoplasms - diagnostic imaging | Protein Conformation | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Receptor Protein-Tyrosine Kinases - chemistry | gatekeeper mutation | crizotinib | ALK-rearranged NSCLC | alectinib (RO5424802 | resistance | ceritinib (LDK378)
Journal Article
Neurology, ISSN 0028-3878, 07/2019, Volume 93, Issue 5, pp. 217 - 219
Journal Article
International Journal of Research in Pharmaceutical Sciences, 2018, Volume 9, Issue 4, pp. 1141 - 1145
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2028 - 2030
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 08/2019, Volume 20, Issue 17, p. 4267
The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing the blood-brain... 
IGF | SHH | NOTCH1 | ATO | WNT | ceritinib
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 26, pp. 2693 - 2701
PurposeIn patients with crizotinib-treated, anaplastic lymphoma kinase gene (ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease... 
ALK | MULTICENTER | SOLID TUMORS | ONCOLOGY | CERITINIB | PHASE-1 TRIAL | CRIZOTINIB | OPEN-LABEL | WHOLE-BODY | SINGLE-ARM | CHEMOTHERAPY
Journal Article
CLINICAL NUCLEAR MEDICINE, ISSN 0363-9762, 11/2016, Volume 41, Issue 11, pp. 879 - 879
Anaplastic lymphoma kinase (AM) positive non small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib.... 
INHIBITOR CERITINIB | NSCLC | PET/CT | F-18-FDG | RECEPTOR | CRIZOTINIB RESISTANCE | ceritinib | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 11/2017, Volume 26, Issue 22, pp. 2719 - 2725
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2016, Volume 6, Issue 10, pp. 1118 - 1133
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 31, p. 22137
Anaplastic lymphoma kinase ( ) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the... 
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 02/2019, Volume 163, pp. 169 - 182
The emergence of various drug-resistant ( ) strains has necessitated the exploration of new drugs that lack cross-resistance with existing therapeutics. By... 
Pyrimidine derivatives | Dihydrofolate reductase inhibitors | Antimycobacterial | Ceritinib | CHEMISTRY, MEDICINAL | TRIMETHOPRIM | BIOLOGICAL EVALUATION
Journal Article
Revue des Maladies Respiratoires Actualites, ISSN 1877-1203, 05/2015, Volume 7, Issue 2, pp. 138 - 145
Screening, targeted therapies, mutations, maintenance. . . Thoracic oncology is progressing quickly. This trend was confirmed in 2014, with important... 
Crizotinib | Ramucirumab | Ceritinib | Nintedani
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.